Project Grant K01HL186068
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $174K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Heart Lung and Blood Institute awarded New York University School of Medicine $186,706 for a K23 Career Development Award on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will evaluate multi-level contexts and barriers affecting primary care clinicians' prescribing of remote patient monitoring (RPM) for hypertension management, then design and test an electronic health record-based prescribing workflow (EHR-RPM) to increase RPM...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital $171,600 on September 1, 2026, under CFDA 93.837 (Cardiovascular Diseases Research) to support career development and mentored research in pediatric obstructive sleep apnea diagnostics. The award funds the recipient investigator's training in three areas: predictive modeling and machine learning, advanced physiological signal analysis, and implementation science for translating research into clinical...
- The National Heart, Lung, and Blood Institute awarded $338,934 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, on September 18, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) for a K01 mentored career development award titled "Start Strong: A Mixed Methods Study to Inform Initial Antihypertensive Prescribing and a Patient-Self Titration Intervention to Improve Blood Pressure Control, Safety, and Reduce Cardiovascular...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Heart, Lung, and Blood Institute awarded President and Fellows of Harvard College $133,232 on June 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate neural control of cardiovascular physiology via heart-to-brain signaling pathways. The recipient, operating through Harvard Medical School's Office of Research Administration, will conduct research to elucidate how genetically distinct populations of vagal cardiac sensory neurons detect and respond...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $330,176 on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mentored research on the effect of severe obesity on regional lung perfusion in acute hypoxemic respiratory failure. The award funds two primary research aims. Aim 1 defines the association between severe obesity and regional lung perfusion in a novel...
- The National Heart, Lung, and Blood Institute awarded Wake Forest University Health Sciences $881,454 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish relationships between poor access to healthy food, inadequate clinical care, and hypertension progression in youth, and to identify strategies to overcome these barriers. The award supports research under the Study of the Epidemiology of Pediatric Hypertension (SUPERHERO) Registry, a longitudinal...
- The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease. The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $133,220 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct an ancillary study characterizing the burden and nature of 11-beta-hydroxysteroid dehydrogenase type 2 (11βHSD2) insufficiency in people with diabetes at risk for chronic kidney disease. The study examines how cortisol-mediated mineralocorticoid receptor (MR) activation contributes to chronic kidney...